Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

January 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Solid TumorSolid Tumor, Adult

Interventions

BIOLOGICAL

Sargramostim

Sargramostim for injection

BIOLOGICAL

Ipilimumab-containing therapy

Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..

Trial Locations (1)

Partner Therapeutics - No Currently Active Sites, Lexington